Bastiaan Privé, MD, Radboud University Medical Centre, and Scott Tagawa, MD, Weill Cornell Medicine, discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic hormone sensitive prostate cancer.
Following surgery and external beam radiotherapy, this option has the potential to become a third MDT option for oligometastatic prostate cancer patients to prolong an ADT-free interval.
Following surgery and external beam radiotherapy, this option has the potential to become a third MDT option for oligometastatic prostate cancer patients to prolong an ADT-free interval.
- Categoria
- Oncology
Commenta per primo questo video.









